{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:08:31Z","timestamp":1768583311502,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T00:00:00Z","timestamp":1498521600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s40618-017-0718-7","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T15:47:39Z","timestamp":1498578459000},"page":"193-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves\u2019 orbitopathy (GO): a new frontier for GO treatment?"],"prefix":"10.1007","volume":"41","author":[{"given":"G.","family":"Rotondo Dottore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ionni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Menconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Casini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sellari-Franceschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Vitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Marcocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Marin\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,27]]},"reference":[{"key":"718_CR1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS (2010) Graves\u2019 ophthalmopathy. N Engl J Med 362:726\u2013738","journal-title":"N Engl J Med"},{"key":"718_CR2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrendo.2013.193","volume":"9","author":"L Bartalena","year":"2013","unstructured":"Bartalena L (2013) Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 9:724\u2013734","journal-title":"Nat Rev Endocrinol"},{"key":"718_CR3","first-page":"444","volume":"36","author":"E Piantanida","year":"2013","unstructured":"Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves\u2019 orbitopathy in the XXI century. J Endocrinol Invest 36:444\u2013449","journal-title":"J Endocrinol Invest"},{"key":"718_CR4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/thy.2014.0475","volume":"25","author":"M Leo","year":"2015","unstructured":"Leo M, Menconi F, Rocchi R, Latrofa F, Sisti E, Profilo MA, Mazzi B, Albano E, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M (2015) Role of the underlying thyroid disease on the phenotype of Graves\u2019 orbitopathy in a tertiary referral center. Thyroid 25:347\u2013351","journal-title":"Thyroid"},{"key":"718_CR5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40618-015-0241-7","volume":"38","author":"E Sisti","year":"2015","unstructured":"Sisti E, Menconi F, Leo M, Profilo MA, Mautone T, Mazzi B, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M (2015) Long-term outcome of Graves\u2019 orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Invest 38:661\u2013668","journal-title":"J Endocrinol Invest"},{"key":"718_CR6","doi-asserted-by":"crossref","unstructured":"Menconi F, Leo M, Sabini E, Mautone T, Nardi M, Sainato A, Sellari-Franceschini S, Vitti P, Marcocci C, Marin\u00f2 M (2016) Natural history of Graves\u2019 orbitopathy after treatment. Endocrine (in press)","DOI":"10.1007\/s12020-016-1136-x"},{"key":"718_CR7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40618-017-0608-z","volume":"40","author":"L Bartalena","year":"2017","unstructured":"Bartalena L, Veronesi G, Krassas GE, Wiersinga WM, Marcocci C, Marin\u00f2 M, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Curr\u00f2 N, Boschi A, Bernard M, von Arx G, Perros P, Kahaly GJ, European Group on Graves\u2019 Orbitopathy (EUGOGO) (2017) Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves\u2019 orbitopathy? J Endocrinol Invest 40:547\u2013553","journal-title":"J Endocrinol Invest"},{"key":"718_CR8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves\u2019 Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association\/European Group on Graves\u2019 orbitopathy guidelines for the management of graves\u2019 orbitopathy. Eur Thyroid J 5:9\u201326","journal-title":"Eur Thyroid J"},{"key":"718_CR9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/thy.2013.0240","volume":"24","author":"F Menconi","year":"2014","unstructured":"Menconi F, Profilo MA, Leo M, Sisti E, Altea MA, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M (2014) Spontaneous improvement of untreated mild Graves\u2019 ophthalmopathy: Rundle\u2019s curve revisited. Thyroid 24:60\u201366","journal-title":"Thyroid"},{"key":"718_CR10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40618-016-0555-0","volume":"40","author":"P Anagnostis","year":"2017","unstructured":"Anagnostis P, Boboridis K, Adamidou F, Kita M (2017) Natural course of mild Graves\u2019 orbitopathy: is it a chronic remitting or a transient disease? J Endocrinol Invest 40:257\u2013261","journal-title":"J Endocrinol Invest"},{"key":"718_CR11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.82.7.773","volume":"82","author":"CB Terwee","year":"1998","unstructured":"Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM (1998) Development of a disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: the GO-QOL. Br J Ophthalmol 82:773\u2013779","journal-title":"Br J Ophthalmol"},{"key":"718_CR12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96:320\u2013332","journal-title":"J Clin Endocrinol Metab"},{"key":"718_CR13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-14-0712","volume":"172","author":"E Sisti","year":"2015","unstructured":"Sisti E, Coco B, Menconi F, Leo M, Rocchi R, Latrofa F, Profilo MA, Mazzi B, Albano E, Vitti P, Marcocci C, Brunetto M, Marin\u00f2 M (2015) Intravenous glucocorticoid therapy for Graves\u2019 ophthalmopathy and acute liver damage: an epidemiological study. Eur J Endocrinol 172:269\u2013276","journal-title":"Eur J Endocrinol"},{"key":"718_CR14","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1089\/thy.2015.0061","volume":"25","author":"E Sisti","year":"2015","unstructured":"Sisti E, Coco B, Menconi F, Leo M, Rocchi R, Latrofa F, Profilo MA, Mazzi B, Vitti P, Marcocci C, Brunetto M, Marin\u00f2 M (2015) Age and dose are major risk factors for liver damage associated with intravenous glucocorticoid pulse therapy for Graves\u2019 orbitopathy. Thyroid 25:846\u2013850","journal-title":"Thyroid"},{"key":"718_CR15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12020-016-0928-3","volume":"54","author":"M Moleti","year":"2016","unstructured":"Moleti M, Giuffrida G, Sturniolo G, Squadrito G, Campenn\u00ec A, Morelli S, Puxeddu E, Sisti E, Trimarchi F, Vermiglio F, Marin\u00f2 M (2016) Acute liver damage following intravenous glucocorticoid treatment for Graves\u2019 ophthalmopathy. Endocrine 54:259\u2013268","journal-title":"Endocrine"},{"key":"718_CR16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40618-016-0518-5","volume":"39","author":"E Sabini","year":"2016","unstructured":"Sabini E, Sisti E, Coco B, Leo M, Ionni I, Menconi F, Profilo MA, Mazzi B, Rocchi R, Latrofa F, Vitti P, Brunetto M, Marcocci C, Marin\u00f2 M (2016) Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves\u2019 orbitopathy. J Endocrinol Invest 39:1323\u20131327","journal-title":"J Endocrinol Invest"},{"key":"718_CR17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1006\/exer.1997.0353","volume":"65","author":"HB Burch","year":"1997","unstructured":"Burch HB, Lahiri S, Bahn RS, Barnes S (1997) Superoxide radical production stimulates retroocular fibroblast proliferation in Graves\u2019 ophthalmopathy. Exp Eye Res 65:311\u2013316","journal-title":"Exp Eye Res"},{"key":"718_CR18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/jcem.74.4.1532179","volume":"74","author":"AE Heufelder","year":"1992","unstructured":"Heufelder AE, Wenzel BE, Bahn RS (1992) Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves\u2019 retroocular fibroblasts. J Clin Endocrinol Metab 74:737\u2013742","journal-title":"J Clin Endocrinol Metab"},{"key":"718_CR19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/thy.1999.9.297","volume":"9","author":"R Lu","year":"1999","unstructured":"Lu R, Wang P, Wartofsky L, Sutton BD, Zweier JL, Bahn RS, Garrity J, Burman KD (1999) Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves\u2019 ophthalmopathy patients. Thyroid 9:297\u2013303","journal-title":"Thyroid"},{"key":"718_CR20","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W (2011) Selenium and the course of mild Graves\u2019 orbitopathy. N Engl J Med 364:1920\u20131931","journal-title":"N Engl J Med"},{"key":"718_CR21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40618-016-0559-9","volume":"40","author":"M Leo","year":"2017","unstructured":"Leo M, Bartalena L, Rotondo Dottore G, Piantanida E, Premoli P, Ionni I, Di Cera M, Masiello E, Sassi L, Tanda ML, Latrofa F, Vitti P, Marcocci C, Marin\u00f2 M (2017) Effects of selenium on short-term control of hyperthyroidism due to Graves\u2019 disease treated with methimazole: results of a randomized clinical trial. J Endocrinol Invest 40:281\u2013287","journal-title":"J Endocrinol Invest"},{"key":"718_CR22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40618-016-0535-4","volume":"40","author":"D Esposito","year":"2017","unstructured":"Esposito D, Rotondi M, Accardo G, Vallone G, Conzo G, Docimo G, Selvaggi F, Cappelli C, Chiovato L, Giugliano D, Pasquali D (2017) Influence of short-term selenium supplementation on the natural course of Hashimoto\u2019s thyroiditis: clinical results of a blinded placebo-controlled randomized prospective trial. J Endocrinol Invest 40:83\u201389","journal-title":"J Endocrinol Invest"},{"key":"718_CR23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40618-016-0505-x","volume":"39","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Chiovato L, Vitti P (2016) Management of hyperthyroidism due to Graves\u2019 disease: frequently asked questions and answers (if any). J Endocrinol Invest 39:1105\u20131114","journal-title":"J Endocrinol Invest"},{"key":"718_CR24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/thy.2016.0397","volume":"27","author":"G Rotondo Dottore","year":"2017","unstructured":"Rotondo Dottore G, Leo M, Casini G, Latrofa F, Cestari L, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M (2017) Antioxidant actions of selenium in orbital fibroblasts: a basis for the effects of selenium in Graves\u2019 orbitopathy. Thyroid 27:271\u2013278","journal-title":"Thyroid"},{"key":"718_CR25","first-page":"927","volume":"19","author":"CC Tsai","year":"2013","unstructured":"Tsai CC, Wu SB, Kao SC, Kau HC, Lee FL, Wei YH (2013) The protective effect of antioxidants on orbital fibroblasts from patients with Graves\u2019 ophthalmopathy in response to oxidative stress. Mol Vis 19:927\u2013934","journal-title":"Mol Vis"},{"key":"718_CR26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11010-006-9230-7","volume":"292","author":"GM Campo","year":"2006","unstructured":"Campo GM, Avenoso A, Campo S, Angela D, Ferlazzo AM, Calatroni A (2006) TNF-alpha, IFN-gamma, and IL-1beta modulate hyaluronan synthase expression in human skin fibroblasts: synergistic effect by concomital treatment with FeSO4 plus ascorbate. Mol Cell Biochem 292:169\u2013178","journal-title":"Mol Cell Biochem"},{"key":"718_CR27","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39:1003\u20131018","journal-title":"Immunity"},{"key":"718_CR28","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/s-0035-1555762","volume":"47","author":"RS Bahn","year":"2015","unstructured":"Bahn RS (2015) Current insights into the pathogenesis of Graves\u2019 ophthalmopathy. Horm Metab Res 47:773\u2013778","journal-title":"Horm Metab Res"},{"key":"718_CR29","doi-asserted-by":"crossref","unstructured":"Rotondo Dottore G, Chiarini R, De Gregorio M, Leo M, Casini G, Cestari L, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M (2017) Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in Graves\u2019 orbitopathy. Endocrine (in press)","DOI":"10.1007\/s12020-017-1255-z"},{"key":"718_CR30","first-page":"521","volume":"34","author":"S Lisi","year":"2011","unstructured":"Lisi S, Botta R, Lemmi M, Sellari-Franceschini S, Altea MA, Sisti E, Casini G, Nardi M, Marcocci C, Pinchera A, Marin\u00f2 M (2011) Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid. J Endocrinol Invest 34:521\u2013527","journal-title":"J Endocrinol Invest"},{"key":"718_CR31","first-page":"696","volume":"60","author":"XL Tang","year":"2005","unstructured":"Tang XL, Liu XJ, Sun WM, Zhao J, Zheng RL (2005) Oxidative stress in Graves\u2019 disease patients and antioxidant protection against lymphocytes DNA damage in vitro. Pharmazie 60:696\u2013700","journal-title":"Pharmazie"},{"key":"718_CR32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 47:9\u201314","journal-title":"Clin Endocrinol (Oxf)"},{"key":"718_CR33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1089\/thy.2012.0373","volume":"23","author":"R Botta","year":"2013","unstructured":"Botta R, Lisi S, Marcocci C, Sellari-Franceschini S, Rocchi R, Latrofa F, Menconi F, Altea MA, Leo M, Sisti E, Casini G, Nardi M, Pinchera A, Vitti P, Marin\u00f2 M (2013) Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts. Thyroid 23:92\u201396","journal-title":"Thyroid"},{"key":"718_CR34","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJM198604033141407","volume":"314","author":"M Levine","year":"1986","unstructured":"Levine M (1986) New concepts in the biology and biochemistry of ascorbic acid. N Engl J Med 314:892\u2013902","journal-title":"N Engl J Med"},{"key":"718_CR35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s000180300001","volume":"60","author":"M Zafarullah","year":"2003","unstructured":"Zafarullah M, Li WQ, Sylvester J, Ahmad M (2003) Molecular mechanisms of N-acetyl-l-cysteine actions. Cell Mol Life Sci 60:6\u201320","journal-title":"Cell Mol Life Sci"},{"key":"718_CR36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.biocel.2005.08.020","volume":"38","author":"R Hardeland","year":"2006","unstructured":"Hardeland R, Pandi-Perumal SR, Cardinali DP (2006) Melatonin. Int J Biochem Cell Biol 38:313\u2013316","journal-title":"Int J Biochem Cell Biol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-017-0718-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T06:36:07Z","timestamp":1569566167000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-017-0718-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,27]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["718"],"URL":"https:\/\/doi.org\/10.1007\/s40618-017-0718-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,27]]}}}